Cue Biopharma (CUE)vsRevolution Medicines Inc (RVMD)
CUE
Cue Biopharma
$29.46
-0.61%
HEALTHCARE · Cap: $124.50M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Cue Biopharma generates 4311% more annual revenue ($32.73M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -59.7%. CUE earns a higher WallStSmart Score of 30/100 (F).
CUE
Avoid30
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1251.0% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -90.3% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CUE
The strongest argument for CUE centers on Revenue Growth, Debt/Equity. Revenue growth of 1251.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CUE profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
CUE carries more volatility with a beta of 2.39 — expect wider price swings.
CUE is growing revenue faster at 1251.0% — sustainability is the question.
CUE generates stronger free cash flow (-11M), providing more financial flexibility.
Bottom Line
CUE scores higher overall (30/100 vs 24/100) and 1251.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?